World Investment Advisors Reduces Position in Medtronic PLC $MDT

World Investment Advisors decreased its position in Medtronic PLC (NYSE:MDT) by 13.6% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 144,641 shares of the medical technology company’s stock after selling 22,762 shares during the period. World Investment Advisors’ holdings in Medtronic were worth $12,533,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Argos Wealth Advisors LLC lifted its stake in Medtronic by 20.9% in the first quarter. Argos Wealth Advisors LLC now owns 2,631 shares of the medical technology company’s stock worth $228,000 after acquiring an additional 454 shares during the period. Turtle Creek Wealth Advisors LLC increased its position in Medtronic by 9.4% during the 1st quarter. Turtle Creek Wealth Advisors LLC now owns 8,468 shares of the medical technology company’s stock valued at $734,000 after purchasing an additional 731 shares during the period. Private Advisor Group LLC increased its position in Medtronic by 0.8% during the 1st quarter. Private Advisor Group LLC now owns 155,511 shares of the medical technology company’s stock valued at $13,475,000 after purchasing an additional 1,297 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in Medtronic by 57.6% in the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 292,779 shares of the medical technology company’s stock worth $25,369,000 after purchasing an additional 107,000 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC raised its holdings in Medtronic by 152.5% in the 1st quarter. Elevation Point Wealth Partners LLC now owns 74,439 shares of the medical technology company’s stock worth $6,485,000 after purchasing an additional 44,964 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on MDT. Sanford C. Bernstein cut their target price on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a research note on Thursday, June 4th. Robert W. Baird decreased their price target on shares of Medtronic from $93.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. TD Cowen restated a “buy” rating and issued a $119.00 price objective on shares of Medtronic in a report on Thursday, June 4th. Citigroup cut their price objective on Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Finally, Rothschild & Co Redburn reduced their target price on Medtronic from $111.00 to $106.00 and set a “buy” rating on the stock in a report on Friday, June 5th. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $99.00.

Insider Activity

In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the sale, the executive vice president owned 37,227 shares in the company, valued at $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Medtronic Trading Down 0.1%

Shares of NYSE MDT opened at $83.07 on Friday. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The firm has a 50-day moving average of $79.04 and a 200 day moving average of $89.06. The stock has a market cap of $106.33 billion, a P/E ratio of 22.27, a price-to-earnings-growth ratio of 2.23 and a beta of 0.56.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The business had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter in the prior year, the company earned $1.62 earnings per share. The business’s revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, sell-side analysts expect that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, June 26th. This represents a $2.88 dividend on an annualized basis and a yield of 3.5%. This is an increase from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is 77.21%.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Investors continue to reward Medtronic’s stronger-than-expected fiscal Q4 results and improved fiscal 2027 outlook, which included solid revenue growth and guidance that supports a more constructive growth narrative for the stock.
• Positive Sentiment: Medtronic expanded its partnership with Retia Medical to distribute the Argos cardiac output monitor more broadly, supporting growth in high-acuity cardiovascular and critical-care markets and reinforcing the company’s expansion into higher-growth device categories. Article Title
• Positive Sentiment: Analyst sentiment remains favorable, with recent coverage showing a “Moderate Buy” tone and several firms maintaining bullish ratings, which may be helping support the share price. Article Title
• Neutral Sentiment: Articles discussing why MDT is up since its last earnings report suggest the move may be a continuation of post-earnings buying rather than a reaction to a fresh catalyst, indicating momentum more than a new surprise. Article Title
• Neutral Sentiment: Medtronic has begun notifying people affected by a cyberattack, but the company said there is no evidence the accessed data was posted online and no impact to patient safety or core operations has been identified so far. Article Title
• Negative Sentiment: The cybersecurity incident still introduces headline risk and potential reputational or legal concerns, even though Medtronic says the event has not affected operations.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).